

MYPERIOPATH®
FINAL REPORT

Doe, John
 Date Of Birth: 09/20/1980 (36 yrs)
 Gender: Male
 Patient Id:
 Patient Location:

Ordering Provider
 Ronald McGlennen MD
 7400 Flying Cloud Drive
 Eden Prairie, MN 55344
 855-672-5362

Sample Information
 Specimen#: 3022131004
 Accession#: 201611-08469
 Specimen: Oral Rinse(P)
 Collected: 11/12/2016 10:30
 Received: 11/13/2016 12:01
 Reported: 11/16/2016 12:30

MYPERIOPATH MOLECULAR ANALYSIS OF PERIODONTAL AND SYSTEMIC PATHOGENS

Result: PATHOGENIC BACTERIA DETECTED, 5 ABOVE THERAPEUTIC THRESHOLD Aa Pg Fn Pi Cs

Bacterial Risk: HIGH - Very strong evidence of increased risk for attachment loss

Legend
 — = Therapeutic Threshold*
 DL = Detection Limit

Result Interpretation: Periodontal disease is caused by specific, or groups of specific bacteria. Threshold levels represent the concentration above which patients are generally at increased risk for attachment loss. Bacterial levels should be considered collectively and in context with clinical signs and other risk factors.

High Risk Pathogens

Moderate Risk Pathogens

Low Risk Pathogens

Pathogen	Result	Clinical Significance
Aa Aggregatibacter actinomycetemcomitans	High	Very strong association with PD: Transmittable, tissue invasive, and pathogenic at relatively low bacterial counts. Associated with aggressive forms of disease.
Pg Porphyromonas gingivalis	High	Very strong association with PD: Transmittable, tissue invasive, and pathogenic at relatively low bacterial counts. Associated with aggressive forms of disease.
Fn Fusobacterium nucleatum/periodonticum	High	Strong association with PD: adherence properties to several oral pathogens; often seen in refractory disease.
Pi Prevotella intermedia	High	Strong association with PD: virulent properties similar to Pg; often seen in refractory disease.
Cs Capnocytophaga species (gingivalis, ochracea, sputigena)	High	Some association with PD: Frequently found in gingivitis. Often found in association with other periodontal pathogens. May increase temporarily following active therapy.
Cr Campylobacter rectus	Low	Moderate association with development of PD: usually found in combination with other suspected pathogens in refractory disease.
Pm Peptostreptococcus (Micromonas) micros	Low	Moderate association with PD: detected in higher numbers at sites of active disease.
Ec Eikenella corrodens	Low	Moderate association with PD: Found more frequently in active sites of disease; often seen in refractory disease.

Not Detected: (Tf) Tannerella forsythia, (Td) Treponema denticola, (En) Eubacterium nodatum

Additional information is available from OralDNA.com

Methodology: Genomic DNA is extracted from the submitted sample and tested for 10 species-specific bacteria and 1 genus of bacteria known to cause periodontal disease. The bacteria are assayed by real-time quantitative polymerase chain reaction (qPCR). Bacterial loads are reported in log copies per mL of sample (e.g. 1x10³ = 1000 bacteria copies per mL of collection). *Modified from: Microbiological goals of periodontal therapy; Periodontology 2000, Vol. 42, 2006, 180-218. This test was developed, and its performance characteristics determined by OralDNA Labs pursuant to CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

OralDNA Labs, A Service of Access Genetics, LLC, 7400 Flying Cloud Drive, Eden Prairie, MN 55344 Phone: 855-672-5362; Fax: 952-942-0703 www.oraldna.com
 CLIA#: 24D1033809 CAP#: 7190878

Web enabled system provided by: access genetics

1 of 2

1

2

3

1 “Result”
 Indication of bacterial pathogens detected above or below threshold

2 “Bacterial Risk”
 Risk of disease progression based on specific bacteria

3 “Therapeutic Threshold”
 The level of bacterial load above which there is a high confidence of a clinically important infection and the consensus to recommend the treatment of that infection. (represented by black lines)

PL-000228-B

MYPERIOPATH®
CLINICAL CONSIDERATIONS

Doe, John
Date Of Birth: 09/20/1980
Gender: Male

Sample Information
Specimen#: 3022131004
Accession#: 201611-08469
Specimen: Oral Rinse(P)
Collected: 11/12/2016

Result: PATHOGENIC BACTERIA DETECTED, 5 ABOVE THERAPEUTIC THRESHOLD

Bacterial Risk: HIGH - Very strong evidence of increased risk for attachment loss

Aa
Pg
Fn
Pi
Cs

High Risk Pathogens

Moderate Risk Pathogens

Low Risk Pathogens

4 Treatment Considerations

- Office Periodontal Therapy:** Protocols to disrupt biofilm and reduce pathogens.
- Systemic Antibiotic Option to Augment Therapy at Clinician's Discretion:**
Clinician to determine if local antimicrobials (e.g. Chlorhexidine) and/or local antibiotics (e.g. Arestin) are sufficient to resolve infection. Published guidelines suggest (subject to allergy, drug interaction, and other medical considerations) the following as a possible adjunct to treatment based on patient's bacterial profile: Amoxicillin 500 mg tid for 8-10 days AND Metronidazole 500 mg bid for 8-10 days, depending on the severity of infection.
Note: The prescribing doctor is responsible for patient therapy. Consider the patient's dental and medical history (e.g. pregnancy/nursing, diabetes, immuno-suppression, other patient medications) when evaluating the use of antibiotic medications. Many antibiotics may impact/interact with other medications and may produce adverse side effects. Review the manufacturer warnings for any contraindications, or consult with the patient's physician if there are concerns with the selected antibiotic regimen.
- Home Care:** Office recommended procedures to daily disrupt biofilm and reduce pathogens.
- Reassessment:** Compare clinical signs and bacterial levels pre- and post-treatment.
- A 2nd sample should be collected six to eight weeks post-therapy.

5 Additional Risk Factors

Clinical	Diagnostic	Medical
BOP <input type="checkbox"/>	Localized <input type="checkbox"/>	Type V Refractory Periodontitis; ADA Code 4900 <input type="checkbox"/>
Inflammation/Swelling <input checked="" type="checkbox"/>	Generalized <input checked="" type="checkbox"/>	Type IV (>6mm); Advanced Periodontitis; ADA Code 4800 <input type="checkbox"/>
Bone Loss <input type="checkbox"/>		Type III (4-6mm); Moderate Periodontitis; ADA Code 4700 <input checked="" type="checkbox"/>
Redness/Discoloration <input type="checkbox"/>		Type II (3-4mm); Mild Periodontitis; ADA Code 4600 <input type="checkbox"/>
Halitosis/Malodor <input type="checkbox"/>		Type I (1-3mm); Gingivitis; ADA Code 4500 <input type="checkbox"/>
		Good Periodontal Health <input type="checkbox"/>
		Family History of PD <input type="checkbox"/>
		Pregnant/Nursing <input type="checkbox"/>
		Immunosuppressed <input type="checkbox"/>
		Diabetes <input type="checkbox"/>
		Cardiovascular Disease <input checked="" type="checkbox"/>
		Current Smoker <input type="checkbox"/>

6 Antibiotic Allergies: None Reported

Tooth Numbers	3	9	14	19	24	30
Pocket Depths	4mm	4mm	5mm	4mm	4mm	3mm

Additional information is available from www.OralDNA.com

Ronald C. McGlennen
Ronald McGlennen MD, FCAP, FACMG, ABMG
Medical Director

OralDNA Labs, A Service of Access Genetics, LLC, 7400 Flying Cloud Drive, Eden Prairie, MN 55344 Phone: 855-672-5362; Fax: 952-942-0703 www.oraldna.com
CLIA#: 24D1033809 CAP#: 7190878

Web enabled system provided by: access genetics

2 of 2

4 Treatment considerations and options to reduce risk

5 Follow-up and additional considerations

6 Links to additional information at www.OralDNA.com